VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma

SUPPLEMENTARY MATERIALS
Supplementary
whereas overexpression of VRK1 promoted, the proliferation and viability of ESCC cells in a time-dependent manner. Statistical analyses were performed using Student's t-test. The results are expressed as the mean ± SD of three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001. and VRK1 overexpression (right) compare to the same conditions treated with 10μg/ml CDDP. Statistical analyses were performed using Student's t-test. The results are expressed as the mean ± SD of three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001.
Supplementary Figure 3: c-Jun enhances CDDP resistance in ESCC cells. The viability of indicated cells was analyzed
by CCK-8 assay in response to 5 μg/ml CDDP in time series. Statistical analyses were performed using Student's t-test. The results are expressed as the mean ± SD of three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001.
Supplementary Figure 4: c-MYC enhances CDDP resistance in ESCC cells. The viability of indicated cells was analyzed
by CCK-8 assay in response to 5μg/ml CDDP in time series. Statistical analyses were performed using Student's t-test. The results are expressed as the mean ± SD of three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001.
Supplementary Figure 5: Luteolin inhibits proliferation of ESCC cells. Luteolin treatment significantly reduced cell viability
of Eca109 and Kyse150 cells in dose-and time-dependent manner, compared with the control group treated with DMSO. Statistical analyses were performed using One-way ANOVA. The results are expressed as the mean ± SD of three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001.
